Misoprostol in the prevention of postpartum hemorrhage

OBJECTIVE: To evaluate the data regarding the use of misoprostol in the prevention of postpartum hemorrhage. DATA SOURCES: Pertinent literature was identified through a MEDLINE search (1966–January 2001) and through other secondary literature databases and/or bibliographies of pertinent articles. DA...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2001-12, Vol.35 (12), p.1648-1652
Main Authors: Mategrano, VA, Gabay, MP
Format: Article
Language:English
Subjects:
Biological and medical sciences
Clinical Trials as Topic
Female
Genital system. Reproduction
Humans
Medical sciences
Misoprostol - therapeutic use
Oxytocics - therapeutic use
Pharmacology. Drug treatments
Postpartum Hemorrhage - etiology
Postpartum Hemorrhage - prevention & control
Pregnancy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: To evaluate the data regarding the use of misoprostol in the prevention of postpartum hemorrhage. DATA SOURCES: Pertinent literature was identified through a MEDLINE search (1966–January 2001) and through other secondary literature databases and/or bibliographies of pertinent articles. DATA SYNTHESIS: New strategies in the prevention of postpartum hemorrhage are being evaluated due to the obstacles surrounding conventional therapies. One therapeutic option is the use of misoprostol. This literature review evaluates the published clinical data involving misoprostol in the prevention of postpartum hemorrhage. Current data suggest that the use of misoprostol for the prevention of postpartum hemorrhage reduces mean estimated blood loss compared with placebo. However, no clinical trials have detected a statistically significant decrease in the incidence of postpartum hemorrhage in misoprostol-treated subjects. There is conflicting evidence regarding the efficacy of misoprostol compared with conventional uterotonics, such as oxytocin or Syntometrine. CONCLUSIONS: In situations where conventional oxytocics are not readily available, storage requirements for oxytocics cannot be met, or the equipment for parenteral administration is not obtainable, misoprostol may be an acceptable prophylactic option.
ISSN:1060-0280
1542-6270
DOI:10.1345/aph.1A100